Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab plus chemoradiotherapy in high‑risk locally advanced SCCHN
CTR20170784Phase 3Suspended
- Sponsor
- Pfizer
- Start
- Jun 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of avelumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Pfizer. Started Jun 2018; status: suspended.
02
Drugs
avelumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20170784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170784.